Our Company
Addressing unmet needs for clinical
validation of medicinal cannabis.
Zelda Therapeutics is an Australian
ASX listed company (ASX: ZLD).
Research Focus
Zelda Therapeutics has been formed to bring together some of the world’s leading researchers and clinicians active in the study and use of medicinal cannabis to treat a variety of ailments.
Latest News
- Notification of cessation of securities - ZLD
- Notification of Expiry of Unlisted Options
- Change of Director's Interest Notice
- Annual Report to shareholders
- Zelira Launches RAF FIVE Acne Treatment Products
- Sequoia Financial Group Report – Zelira FY21 Results and Full Year Review, 9 September 2021
- Australian medicinal cannabis revenue tipped to reach $200 million in 2021 – The West Australian
- 18 Minutes with Zelira Therapeutics – 180 Markets
- 18 Minutes with Zelira Therapeutics – 180 Markets
- Cantor Fitzgerald Hosts Fireside Chat with Zelira Therapeutics
- Cantor Fitzgerald Hosts Fireside Chat with Zelira Therapeutics
- Zelira Therapeutics launches Zenivol™ product in Australia after TGA adds to Special Access Scheme
- Medicinal cannabis trial could help retired AFL players manage chronic pain
- Medicinal cannabis trial could help retired AFL players manage chronic pain
- Sequoia Initiation Research Report, 19 August 2020
- Sequoia Initiation Strong Buy, 19 August 2020
- Proactive – Three medical cannabis companies in focus at Proactive’s webinar on August 11
- Proactive – Three medical cannabis companies in focus at Proactive’s webinar on August 11
- Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints
- Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints
OUR PARTNERS
 |
 |
 |
 |
 |
 |
 |
 |
 |